从LEAP试验系列中学习：优化联合治疗的临床试验设计。

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-05-09 DOI:10.1016/j.medj.2025.100693

Jiatong Ding, Yue Yu, Dandan Cui, Shujun Xing, Dawei Wu, Yuan Fang, Ning Jiang, Peiwen Ma, Yale Jiang, Dongyan Liu, Weijie Yu, Yanjie Han, Jiawei Zhou, Hong Fang, Shuopeng Jia, Qiyu Tang, Shuhang Wang, Ning Li

{"title":"从LEAP试验系列中学习：优化联合治疗的临床试验设计。","authors":"Jiatong Ding, Yue Yu, Dandan Cui, Shujun Xing, Dawei Wu, Yuan Fang, Ning Jiang, Peiwen Ma, Yale Jiang, Dongyan Liu, Weijie Yu, Yanjie Han, Jiawei Zhou, Hong Fang, Shuopeng Jia, Qiyu Tang, Shuhang Wang, Ning Li","doi":"10.1016/j.medj.2025.100693","DOIUrl":null,"url":null,"abstract":"The LEAP trial series examining the synergy of pembrolizumab and lenvatinib across various cancers has yielded mixed results, highlighting the need for a more detailed understanding of combination therapies. By learning from these trials, we aim to advance the clinical development of more effective combination strategies to improve patient outcomes.","PeriodicalId":29964,"journal":{"name":"Med","volume":"6 5","pages":"100693"},"PeriodicalIF":12.8000,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Learning from the LEAP trial series: Optimizing clinical trial design for combination therapies.\",\"authors\":\"Jiatong Ding, Yue Yu, Dandan Cui, Shujun Xing, Dawei Wu, Yuan Fang, Ning Jiang, Peiwen Ma, Yale Jiang, Dongyan Liu, Weijie Yu, Yanjie Han, Jiawei Zhou, Hong Fang, Shuopeng Jia, Qiyu Tang, Shuhang Wang, Ning Li\",\"doi\":\"10.1016/j.medj.2025.100693\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The LEAP trial series examining the synergy of pembrolizumab and lenvatinib across various cancers has yielded mixed results, highlighting the need for a more detailed understanding of combination therapies. By learning from these trials, we aim to advance the clinical development of more effective combination strategies to improve patient outcomes.\",\"PeriodicalId\":29964,\"journal\":{\"name\":\"Med\",\"volume\":\"6 5\",\"pages\":\"100693\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2025-05-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Med\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.medj.2025.100693\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Med","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.medj.2025.100693","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

LEAP试验系列研究了派姆单抗和lenvatinib在各种癌症中的协同作用，结果不一，强调需要更详细地了解联合治疗。通过从这些试验中学习，我们的目标是推进更有效的联合策略的临床开发，以改善患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Learning from the LEAP trial series: Optimizing clinical trial design for combination therapies.

The LEAP trial series examining the synergy of pembrolizumab and lenvatinib across various cancers has yielded mixed results, highlighting the need for a more detailed understanding of combination therapies. By learning from these trials, we aim to advance the clinical development of more effective combination strategies to improve patient outcomes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.